AIDX Short Volume
20/20 Biolabs, Inc. Common Stock (AIDX) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $4.9M, listed on NASDAQ, employing roughly 13 people, carrying a beta of -0.42 to the broader market. 20/20 GeneSystems, Inc. Led by Jonathan Cohen, public since 2023-06-15.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-01
- Short Volume
- 99.1K
- Total Volume
- 165.9K
- Short %
- 59.73%
- 30-Day Avg Short %
- 27.16%
Showing 30 days of FINRA short volume data for 20/20 Biolabs, Inc. Common Stock.
Learn how short volume is reported and how to read the data →
Frequently asked AIDX short volume questions
- What is the daily AIDX short volume?
- As of Jun 1, 2026, 20/20 Biolabs, Inc. Common Stock (AIDX) short volume is 99.1K shares against 165.9K total reported volume, or 59.73% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is AIDX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does AIDX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.